Newron Pharmaceuticals SpA

Newron Pharmaceuticals SpA is a biopharmaceutical company headquartered in Bresso near Milan, Italy, specializing in the development of neuroscience-based treatments. Founded in 1999, the company focuses on advancing innovative therapies from discovery through to market, particularly in the central nervous system and neurological disorders. Its lead compound, evenamide, represents a first-in-class glutamate modulator designed as an add-on therapy for treatment-resistant schizophrenia (TRS) and poorly responding patients. Currently in the global pivotal ENIGMA-TRS Phase III development program, evenamide has shown promising clinical results, including significant improvements in key efficacy measures over time and a favorable safety profile compared to existing antipsychotics. Newron has established strategic partnerships, including development and commercialization agreements with EA Pharma, a subsidiary of Eisai, for Japan and select Asian territories, and Myung In Pharm for South Korea. Under the leadership of CEO Stefan Weber, Newron Pharmaceuticals SpA plays a vital role in addressing unmet needs in psychiatric and neurological conditions within the global biopharmaceutical market.